Loading candles…
Sun Pharmaceutical Industries Ltd is an Indian pharmaceutical company engaged in the manufacturing, development, and marketing of branded and generic pharmaceutical formulations as well as Active Pharmaceutical Ingredients (APIs). Operating within the pharmaceuticals industry, it serves multiple segments including specialty medicines, the Indian market, and emerging markets. The company has manufacturing facilities worldwide and distributes its products to over 100 countries globally. Sun Pharmaceutical Industries Ltd holds the position as the largest pharmaceutical company in India and ranks as the fourth-largest specialty generic company worldwide.
This page is a live market overview for SUN PHARMACEUTICAL IND L (SUNPHARMA) on the NSE. As a listed security, SUN PHARMACEUTICAL IND L is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for SUNPHARMA before placing trades on tick2trade.
As of the latest feed, SUNPHARMA last traded at ₹1,945 on NSE, down ₹6 (0.31%) from the previous close of ₹1,951. Today's session range is ₹1,925.1 – ₹1,957, against a 52-week band of ₹1,548 – ₹2,046.9. Traded volume today stands at 24.25L shares.
The overview consolidates an interactive price chart with multiple time ranges, a near-the-money option chain snapshot, recent market headlines, upcoming corporate events for SUNPHARMA in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether SUNPHARMA is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for SUN PHARMACEUTICAL IND L before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in SUNPHARMA. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated SUNPHARMA option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Audited Results - Q4 & FY26 | To consider and approve the Audited Standalone and Consolidated Financial Results for the quarter and year ended 31 March 2026 and recommendation of final di… | 22 May 2026 |
| Results - Q3-FY25 | To consider and approve the financial results for the quarter and nine months ended 31 December 2025, and the interim dividend for FY 2025-26 | 31 Jan 2026 |
| Unaudited Results - Q2 & FY25 | To consider and approve the Unaudited financial results for the quarter and half year ended 30 September 2025. | 5 Nov 2025 |
| Other | To consider and approve the Unaudited financial results for Q1 of FY 2025-26 | 31 Jul 2025 |
| Results - FY25 | To consider and approve the financial results for the year ended 31 March 2025 and final dividend, if any | 22 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.